EUVIMEDEUVIMED entdecken
Qualitative StudieOpen Access · CC BY-NC-ND 4.0

Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine

Rikki Mangrum iD, Maya T Gerstein iD, Calvin J Hall, Dawn C Buse, Carrie R Houts, James S McGinley, Kelly P McCarrier, Richard B Lipton iD, R J Wirth

Headache: The Journal of Head and Face Pain · 2023-07 · 63 (7) · 953-964

DOI: 10.1111/head.14521 ↗

Kurz gefasst

Qualitative Studie in der Zeitschrift Headache: The Journal of Head and Face Pain, online erschienen am 04.05.2023. Verfasst von Rikki Mangrum und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vector Psychometric Group, Chapel Hill, North Carolina, USA. Hauptthemen laut MEDLINE: Migraine Disorders. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FDA HHS, U.S. Food and Drug Administration.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

There is renewed emphasis on including patients in determining, defining, and prioritizing outcomes for migraine treatment.

Objectives

To obtain insights directly from people living with migraine on their priorities for treatment.

Methods

A total of 40 qualitative interviews were conducted as part of the Migraine Clinical Outcome Assessment System project, a United States Food and Drug Administration grant‐funded program to develop a core set of patient‐centered outcome measures for migraine clinical trials. Interviews included a structured exercise in which participants rank‐ordered pre‐defined lists of potential benefits for acute and preventive migraine therapy. The 40 study participants who reported being diagnosed with migraine by a clinician ranked the benefits and explained their rationale.

Results

Study participants consistently ranked either pain relief or absence of pain as their top priority for acute treatment. Relief/absence of other migraine symptoms and improved functioning were also prioritized. For preventive treatment, participants prioritized reductions in migraine frequency, symptom severity, and attack duration. Few differences were found between participants with episodic migraine and those with chronic migraine. However, participants with chronic migraine ranked “increased predictability of attacks” much higher than those with episodic migraine. Participants' rankings were influenced by prior expectations and experiences of migraine treatments, which caused many participants to deprioritize desired benefits as unrealistic. Participants also identified several additional priorities, including limited side‐effects and reliable treatment efficacy in both acute and preventive treatments.

Conclusion

The results showed the participants prioritized treatment benefits aligned with existing core clinical outcomes used in migraine research, but also valued benefits that are not typically assessed, such as predictability. Participants also deprioritized important benefits when they believed treatment was unlikely to deliver those outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersHumansTreatment OutcomeOutcome Assessment, Health CarePain ManagementPain

Stichwörter der Autor:innen

migraine therapypatient reported outcomesqualitative researchquality of life

Autor:innen und Institutionen

  • Vector Psychometric Group, Chapel Hill, North Carolina, USA.
  • Patient Centered Outcomes, Open Health Group, Bethesda, Maryland, USA.
  • Neurology, Albert Einstein College of Medicine, Bronx, New York, USA.

ORCID-Profile: Rikki Mangrum, Maya T Gerstein, Richard B Lipton

Förderung

  • FDA HHS
  • U.S. Food and Drug Administration

Zitieren

APA

Mangrum, R., Gerstein, M. T., Hall, C. J., Buse, D. C., Houts, C. R., McGinley, J. S., McCarrier, K. P., Lipton, R. B., & Wirth, R. J. (2023). Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine. Headache: The Journal of Head and Face Pain, 63(7), 953-964. https://doi.org/10.1111/head.14521

Vancouver

Mangrum R, Gerstein MT, Hall CJ, Buse DC, Houts CR, McGinley JS, et al. Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine. Headache: The Journal of Head and Face Pain. 2023;63(7):953-964. doi:10.1111/head.14521

BibTeX
@article{Mangrum2023,
  author = {Mangrum, Rikki and Gerstein, Maya T and Hall, Calvin J and Buse, Dawn C and Houts, Carrie R and McGinley, James S and McCarrier, Kelly P and Lipton, Richard B and Wirth, R J},
  title = {Priority acute and preventive migraine treatment benefits: Results of the Migraine Clinical Outcome Assessment System (MiCOAS) qualitative study of people living with migraine},
  journal = {Headache: The Journal of Head and Face Pain},
  year = {2023},
  volume = {63},
  number = {7},
  pages = {953--964},
  doi = {10.1111/head.14521}
}
Kostenlos starten →